Author | Method | Participants | Formulationa | Method of delivery | Outcomes |
---|---|---|---|---|---|
Debin et al. [17] | Patients randomized to BMMSC or standard care | 38 | Autologous BMMSC | Intramuscular and intralesional injections | Increased complete ulcer healing rates in treatment group Increased ABI in treatment group Decreased amputation rates |
Dash et al. [18] | Patients randomized to BMMSC or standard care | 6 | Donor BMMSC | Intramuscular injections, intralesional injections and topical application | Increased ulcer healing rates |
Prochazka et al. [23] | Patients randomized to BMMSC or standard care | 96 | Autologous BMMSC | Intramuscular injections | Decreased amputation rates in treatment group |
Lu et al. [21] | Patients randomized to BMMSC or BMMNC in one limb and saline in the other limb | 41 | Autologous BMMSC Autologous BBMNC | Intramuscular and intralesional injections | Increased complete ulcer healing BMMSC > BMMNC > NS Decreased amputation rates BMMSC > BMMNC > NS |
Jain et al. [19] | Patients randomized to BMMSC or whole Blood | 48 | Autologous BMMSC | Intralesional injection and topical application | Increased complete ulcer healing in treatment groupb |
Kirana et al. [20] | Patients randomized to BMMSC or BMMNC in both limbs | 22 | Autologous BBMSC Autologous BBMNC | Intramuscular injection or Intraarterial injection | Improved TcPO2 from baseline in both groups No significant difference in ulcer healing |
Lu et al. [22]c | Patients randomized to BMMSC or BMMNC in one limb and saline in the other limb | 41 | Autologous BMMSC Autologous BBMNC | Intramuscular and intralesional injections | Decreased incidence of ulcer recurrence for BMMSC (vs. NS) No significant difference in amputation rates |